Engineered γδ T-APC Development ServicesOnline Inquiry
The human γδ T cell is a small group of T lymphocytes carrying a distinctive γδ cell receptor, which has an enhanced antigen-presenting function after activation. With abundant experience in cell bioengineering during the past decades, Creative Biolabs has developed an advanced technology platform to provide rapid and high-quality γδ T-APC development services for clients throughout the world.
Antigen Recognition by γδ T cell
T cell receptor (TCR) expressed on the surface T lymphocyte is a protein complex that is mainly responsible for antigen recognition. Human T cells are divided into two subsets according to the peptide chains that make up TCR, one is αβ T cell with α and β chains TCR and the other is γδ T cell with γ and δ chains TCR.
Fig.1 Structure of human αβ TCR and γδ TCR. (Morath, 2020)
Both the αβ T cell and γδ T cell can recognize a variety of antigens. Commonly αβ T cells recognize peptide antigens presented on the major histocompatibility complex (MHC) on the surface of antigen-presenting cells (APCs), among which CD4+ αβ T cells recognize peptides loaded on MHC class II molecule, whereas CD8+ αβ T cells bind to antigens on MHC class I molecule. Differently and importantly, γδ T cells can recognize a wide range of antigens in an MHC unrestricted manner without antigen processing. Activated γδ T cells can serve as a professional APC, recognizing and reacting with non-peptide antigens, soluble proteins, lipid antigens, MHC and non-MHC loaded antigens, etc.
Engineered γδ T-APC: a New Approach for γδ T Therapy
It has been demonstrated that stimulating γδ T cells with phosphoantigens led to rapid or increased expression of antigen-presenting related markers on the surface of γδ T cells, such as MHC I, MHC II, co-stimulatory molecules, and adhesion receptors.These markers endow γδ T cells with APC-like functions that directly and professionally recognize and process antigens, as well as cytotoxicity through MHC I pathway.
Fig.2 Antigen processing and presentation in γδ T-APCs. (Moser, 2011)
Therefore, by stimulating with phosphoantigens or related ligands, γδ T cells with enhanced antigen-presenting functions (γδ T-APC) can be obtained in vitro, which is similar to and superior to the widely used monocyte-derived dendritic cells, exhibiting great potential for immunotherapy as a cellular vaccine. Based on the γδ T cell generation and development methods, it is not difficult to harvest and expand γδ T-APC on a large scale for clinical applications.
Fig.3 In vitro generation of γδ T-APCs for use in immunotherapy. (Moser, 2011)
Engineered γδ T-APC Development Services in Creative Biolabs
Since the discovery in 1984, γδ T cell therapy has drawn much concentration of researchers in terms of human disease immunotherapy. Creative Biolabs, a leading biotechnology company dedicated to novel therapy discovery, has been recognized as an excellent supplier of immunotherapy. Based on enriched experience, we provide custom engineered γδ T-APC development services for different applications.
For details, please directly contact us, we will offer you the most tailored solutions and support as soon as possible.
- Morath, A., Schamel, W.W. αβ and γδ T cell receptors: Similar but different. Journal of Leukocyte Biology. 2020, 107(6): 1045-1055.
- Moser, B., Eberl, M. γδ T-APCs: a novel tool for immunotherapy? Cellular and Molecular Life Sciences. 2011, 68(14): 2443-2452.